4//SEC Filing
Daugherty Frank Joseph 4
Accession 0001493152-22-017665
CIK 0001799788other
Filed
Jun 23, 8:00 PM ET
Accepted
Jun 24, 8:18 AM ET
Size
5.6 KB
Accession
0001493152-22-017665
Insider Transaction Report
Form 4
Daugherty Frank Joseph
DirectorChief Medical Officer
Transactions
- Award
Stock Options
2022-06-22+104,890→ 104,890 totalExercise: $7.63Exp: 2032-06-22→ Common Stock (104,890 underlying)
Footnotes (1)
- [F1]The options vest over time and pursuant to milestones. 2,185 of the options vest each month for 48 months contingent on the Company meeting certain performance milestones. The Reporting Person is eligible to exercise (i) 25% after the first site is activated for the Phase 3 clinical trial, (ii) 50% after completion of interim analysis of the Phase 3 clinical trial and (iii) 25% upon filing of Biologic License Application with the US Food and Drug Administration.
Documents
Issuer
Greenwich LifeSciences, Inc.
CIK 0001799788
Entity typeother
Related Parties
1- filerCIK 0001806875
Filing Metadata
- Form type
- 4
- Filed
- Jun 23, 8:00 PM ET
- Accepted
- Jun 24, 8:18 AM ET
- Size
- 5.6 KB